Viva Biotech Holdings (SEHK:1873) One Off Gain Clouds Trailing 12.7% Margin Narrative

Viva Biotech Holdings (SEHK:1873) has reported FY 2025 first half revenue of CN¥831.9 million and basic EPS of CN¥0.058, against a backdrop of trailing twelve month revenue of CN¥1.7 billion and EPS of CN¥0.10 that has been associated with earnings growth of 31.4% over the past year and a 16.9% annualised pace over five years. Over the last twelve months, net profit margin has been reported at 12.7% versus 8.4% in the prior year period, so the latest print comes with visibly thicker margins that sharpen the focus on how sustainable this profitability profile might be.

See our full analysis for Viva Biotech Holdings.

With the headline numbers on the table, the next step is to compare them with the main narratives around Viva Biotech Holdings to see which stories hold up and which start to look out of date.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM net income of CN¥219.8 million vs half year pattern

• On a trailing twelve month basis, net income excluding extra items sits at CN¥219.8 million, compared with CN¥121.8 million for FY 2025 H1 and CN¥50.5 million for FY 2024 H2. The rolling number therefore reflects several different half year contributions rather than the latest half alone.
• What stands out for bullish investors is that this rolling profit figure is paired with five year earnings growth of 16.9% per year and 31.4% in the last year. However, the period also includes a one off gain of CN¥152.6 million,
  • This mix of steady multi year earnings growth rates and a material one off item means anyone leaning bullish needs to separate the repeatable CN¥219.8 million earning power from the portion tied to that gain.
  • At the same time, revenue reported at about 20.3% per year growth over the last 12 months gives bulls a concrete top line trend to point to when arguing that the service platform is supporting higher profits over time.

Curious how this earnings profile fits into the wider story that other investors are building around Viva Biotech Holdings? Curious how numbers become stories that shape markets? Explore Community Narratives

12.7% margin and one off gain together shape profitability

• The trailing net profit margin of 12.7% is higher than the prior year’s 8.4%. Because that period also includes a CN¥152.6 million one off gain, the current margin level reflects both underlying operations and that extra item.
• Critics who are cautious about the quality of earnings often point straight to this mix of higher margin and one off benefit,
  • They can point out that while FY 2025 H1 net income of CN¥121.8 million and FY 2024 H1 net income of CN¥116.8 million look fairly similar, the 12.7% trailing margin is being calculated across a period with the CN¥152.6 million gain included.
  • They may also argue that the improvement from 8.4% to 12.7% is harder to interpret when the trailing twelve month revenue figure of CN¥1.7b is lower than the CN¥1.98b level reported for the older trailing period in the dataset, so margin shifts are not purely about cost discipline.

P/E of 17x and 12.9% gap to DCF fair value

• The shares trade on a trailing P/E of 17x at a price of HK$2.01, compared with a DCF fair value estimate of HK$2.31 and industry and peer P/E levels of 34.3x and 38.2x respectively.
• Supporters of the bullish view argue that this combination of a lower P/E and a 12.9% gap to the DCF fair value leaves room for upside if the earnings record holds together,
  • They can point to the five year earnings growth rate of 16.9% per year and the 31.4% growth in the last year as evidence that the CN¥0.10 trailing EPS is not a one off number even after accounting for the CN¥152.6 million gain.
  • They may also highlight that forecast earnings growth of about 38.6% per year, together with a net margin of 12.7%, is not fully reflected in a 17x P/E multiple when many peers in the Asian Life Sciences group are priced at roughly double that level.

Some investors see that 17x P/E against faster historical and forecast earnings growth as the heart of the bullish debate around Viva Biotech Holdings, and they look for a detailed bull case before deciding how much weight to give the numbers in this half year. 🐂 Viva Biotech Holdings Bull Case

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Viva Biotech Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With both risks and rewards in play, the real question is how this mix sits with your own tolerance and goals. Move quickly, review the underlying figures, and weigh both sides using the 4 key rewards and 2 important warning signs

See What Else Is Out There

Viva Biotech Holdings blends a one off CN¥152.6 million gain with thinner revenue of CN¥1.7b, which makes the 12.7% margin and current P/E harder to interpret with confidence.

If you want ideas where earnings quality and valuation may look cleaner, compare this situation with 253 high quality undervalued stocks and see which companies feel more suitable for your portfolio today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com